🇺🇸 nifedipine controlled release tablets in United States

15 US adverse-event reports

Safety signals — FAERS

Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.

• Window: 22 April 2025 – 22 April 2026
• Total reports: 15

Most-reported reactions

1. Encephalopathy — 3 reports (20%)
2. Diarrhoea — 2 reports (13.33%)
3. Gastrointestinal Haemorrhage — 2 reports (13.33%)
4. Myelosuppression — 2 reports (13.33%)
5. Abdominal Distension — 1 report (6.67%)
6. Abdominal Pain — 1 report (6.67%)
7. Anaemia — 1 report (6.67%)
8. Aortic Dissection — 1 report (6.67%)
9. Cerebral Haemorrhage — 1 report (6.67%)
10. Cerebral Infarction — 1 report (6.67%)

Source database →

Frequently asked questions

Is nifedipine controlled release tablets approved in United States?

nifedipine controlled release tablets does not currently have US marketing authorisation in our dataset.

Who is the marketing authorisation holder for nifedipine controlled release tablets in United States?

Guangzhou First People's Hospital is the originator. The local marketing authorisation holder may differ — check the official source linked above.